ReNerve Secures Marketing Approval in India
Filed with ASX · · 4 pages · English
Summary by 6ix AI
ReNerve Limited has announced that it has received marketing approval for its NervAlign Nerve Cuff in India, marking a significant milestone for the company. This approval from India's Central Drugs Standard Control Organization allows ReNerve and its partner, NetCentrix Ventures, to begin commercial rollout in the Indian market. The Indian nerve repair market is substantial, driven by a high incidence of road trauma, making this approval a key step in ReNerve's global strategy. Dr. Julian Chick, CEO of ReNerve, emphasized the importance of this approval in addressing the clinical need for effective peripheral nerve repair in India.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Renerve
- ReNerve Secures Marketing Approval in the Philippines
- Q4 FY26 Activities Report and Appendix 4C
- ReNerve Secures up to A$5 Million Funding Facility
- ReNerve Secures Marketing Approval in Indonesia
- ReNerve appoints J4 as second Empliq manufacturing partner
Later from Renerve
- ReNerve and RMIT awarded $499k grant
- ReNerve completes first cases in Hong Kong and Malaysia
- ReNerve AGM Presentation
- Positive FDA Feedback on NervAlign Nerve Guide Matrix
- Positive 12-Month Data for NervAlign Nerve Guide Matrix
Follow Renerve into a list and get an email when it puts out news.
Follow Renerve